19:03 IST
NSE
Employee Stock Options
Cipla Employee Stock Options
Cipla allotted 12,168 equity shares following the exercise of options under its ESOS and ESAR schemes. This increases the company's total paid-up share capital.
Cipla Ltd
- Share price
- ₹1,340.20
- Market cap
- ₹1,08,271 Cr
- Revenue (annual)
- ₹28,163 Cr
- Net profit (annual)
- ₹3,879 Cr
- P/E (TTM)
- 32.1×Sector 47.4×
- Promoter holding
- 29.21%+0.00% QoQ
- FII holding
- 20.20%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Other Announcement 2Employee Stock Options 2Acquisition 2Partnership 1Merger & Restructuring 1Management Change 1Business Update 1
Time
10 announcements with these filters
22:56 IST
BSE
Management Change
Cipla Management Change
Cipla Ltd announced that Mr. Venkata Sai Mungara has transitioned to a subsidiary role, ceasing to be a Senior Management Personnel effective October 1, 2026.
17:32 IST
NSE
Other Announcement
Cipla Other Announcement
Cipla announced it was assigned an ESG rating of 68 by Niche Ninety Nine Capability and Certifications (OPC) Private Limited, a SEBI-registered rating provider.
16:43 IST
BSE
Acquisition
Cipla Acquisition
Cipla is notifying shareholders and creditors about a Scheme of Amalgamation with Inzpera Healthsciences, providing them an opportunity to submit representations to the NCLT.
15:42 IST
BSE
Partnership
Cipla Partnership
Cipla signed an exclusive licensing and supply agreement with SBP Group’s CTTQ for the drug Rolditamig Deuderuxtecan. This collaboration aims to accelerate therapy access in licensed markets.
20:15 IST
BSE
Merger & Restructuring
Cipla Merger & Restructuring
Cipla Ltd. announced an internal restructuring where Aspergen Limited, India, acquired a 100% stake in Aspergen Inc., USA, from existing group subsidiaries.
17:35 IST
NSE
Employee Stock Options
Cipla Employee Stock Options
Cipla allotted 5,281 equity shares to employees upon exercise of options under its ESOS and ESAR schemes.
16:02 IST
BSE
Business Update
Cipla Business Update
Cipla reported receiving seven inspectional observations from the USFDA following a cGMP inspection at its Pithampur facility. The company intends to address these observations promptly.
17:01 IST
NSE
Acquisition
Cipla Acquisition
Cipla Ltd announced that the NCLT has allowed the scheme application for the amalgamation of its wholly-owned subsidiary, Inzpera Healthsciences Ltd, into Cipla Ltd.
13:25 IST
NSE
Other Announcement
Cipla Other Announcement
Cipla Limited received updated ESG ratings from SES and NSE. SES assigned a score of 69.9 while NSE assigned 67 for the FY 2025-26 period.